ArticleActa dermato-venereologica2025
Identification of Stigmatization and Relevant Predictors in People with Alopecia Areata and Androgenetic Alopecia: A Comparative Cross-sectional Study in German-speaking Countries and the USA.
Article in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stigmatization of skin conditions like alopecia areata (AA) and androgenetic alopecia (AGA) impairs quality of life (QoL), but research is limited. The aim of this study was to compare stigmatization and QoL in individuals with AA and AGA in German-speaking (GS) and US samples and identify stigmatization predictors. This cross-sectional online survey included AA and AGA participants from GS countries (April-August 2020) and the USA (May-August 2021). Stigmatization and QoL were assessed using the Perceived Stigmatization Questionnaire (PSQ) and Hairdex, along resilience, happiness, and social support assessment tools. Regression analyses evaluated disease severity, duration, age, gender, marital status, and social support as stigmatization predictors. All subgroups perceived stigmatization and impaired QoL. GS-AA (n = 423, 93.6% women) participants perceived more stigma but better QoL than GS-AGA (n = 102, 79.4% women). The US sample (AA: n = 199, 84.4% women; AGA: n = 47, 93.6% women) showed similar trends, though insignificant. GS participants reported higher stigma and US participants lower QoL. Stigmatization was associated with being male, younger, employed, severe disease, daily-life restrictions, and anxiety. Both samples were predominantly female, with the US sample being older and smaller, potentially reducing significance. In conclusion, sociodemographics and gender influence stigmatization and QoL. Interventions should enhance resilience and social support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.